New Hemostatic Agents: Perioperative Anesthetic Considerations

Author(s): Antonia-Therese Kietaibl, Sibylle Kietaibl*.

Journal Name: Current Pharmaceutical Design

Volume 25 , Issue 19 , 2019


Abstract:

Aim: Pharmacologic agents with procoagulant effects and antidotes against antithrombotic drugs play an important role in the prevention and management of perioperative coagulopathic bleeding. The aim of this narrative review is knowledge transfer from new and renewed hemostatic agents to anesthesiologists and other physicians involved in perioperative medicine.

Methods: The literature search was performed on PubMed and the Summaries of Product Characteristics of 6 pharmacologic agents of interest: fibrinogen concentrate, vonicog alfa, susoctocog alfa, idarucizumab, andexanet alfa, and argatroban.

Results and Discussion: This review highlights renewed interest in fibrinogen concentrate, an old prohemostatic drug, in correcting hypofibrinogenemia which is a leading pathomechanism of perioperative bleeding.

This review describes clinically relevant aspects for brand new recombinant prohemostatic drugs for their use in critical clinical situations: vonicog alfa for the prevention and correction of bleeding in von Willebrand syndrome, and susoctocog alfa in acquired hemophilia A.

Clinical experience and increasing evidence broadened the field of applications of the old antithrombotic drug argatroban to heparin resistance.

New antidotes against new antithrombotic agents revolutionized the safety of chronic antithrombotic therapy in the emergency situations of acute and trauma surgery.

Information on dosing and handling of new hemostatic drugs is summarized.

Conclusion: New and potent hemostatic agents exist for perioperative use and may enrich the armamentarium of anesthesiologists. Implementation into clinical practice requires their availability and user knowledge. Sustainability of these new drugs depends on post-licensing research, cost-effectiveness, and clinical experience.

Keywords: Perioperative medicine, fibrinogen concentrate, vonicog alfa, susoctocog alfa, idarucizumab, andexanet alfa, argatroban.

[1]
Kozek-Langenecker SA. Monitoring of hemostasis in emergency medicine. Yearbook of Intensive Care and Emergency Medicine: Springer-Verlag Heidelberg 2007; 847-60.
[2]
Kozek-Langenecker SA, Ahmed AB, Afshari A, et al. Management of severe perioperative bleeding: Guidelines from the European Society of Anaesthesiology: First update 2016. Eur J Anaesthesiol 2017; 34(6): 332-95.
[http://dx.doi.org/10.1097/EJA.0000000000000630] [PMID: 28459785]
[3]
Bundesministerium für Gesundheit und Frauen Qualitätsstandard patient blood management 2016.http://www.oeglmkc.at/down/QS %20Patient%20Blood%20Managment%20Endbericht%20final.pdf
[4]
Patient Blood Management https://www. patientbloodmanagement.de/.
[5]
Shander A, Javidroozi M. Blood conservation strategies and the management of perioperative anaemia. Curr Opin Anaesthesiol 2015; 28(3): 356-63.
[http://dx.doi.org/10.1097/ACO.0000000000000179] [PMID: 25827281]
[6]
Kietaibl SA. Fibrinogen replacement therapy in acquired and perioperative bleeding. In: Uni-Med Verlag AG Bremen London Boston 1st ed. 2018.
[7]
Rossaint R, Bouillon B, Cerny V, et al. The European guideline on management of major bleeding and coagulopathy following trauma. In: Crit Care . 2016.
[8]
Schlimp C. Fibrinogen Replacement: Plasma, Cryoprecipitate, Concentrate.. Fibrinogen replacement therapy in acquired and perioperative bleeding. In: Kietaibl SA, Ed Uni-Med Verlag AG Bremen London Boston. 2018; pp. 64-9.
[9]
Kozek-Langenecker S, Sørensen B, Hess JR, Spahn DR. Clinical effectiveness of fresh frozen plasma compared with fibrinogen concentrate: a systematic review. Crit Care 2011; 15(5): R239.
[http://dx.doi.org/10.1186/cc10488] [PMID: 21999308]
[10]
Levy JH, Grottke O, Fries D, Kozek-Langenecker S. Therapeutic plasma transfusion in bleeding patients: A systematic review. Anesth Analg 2017; 124(4): 1268-76.
[http://dx.doi.org/10.1213/ANE.0000000000001897] [PMID: 28319549]
[11]
Lance M. Factor Concentrates (Fibrinogen, PCC, FXIII) versus FFP in Patient Blood Management.. Fibrinogen replacement therapy in acquired and perioperative bleeding. In: Kietaibl SA, Ed Uni-Med Verlag AG Bremen London Boston . 2018; pp. 70-6.
[12]
Ahmed AB, Nascimento B. Factor Concentrates (Fibrinogen, PCC, FXIII) versus Cryoprecipitate.. Fibrinogen replacement therapy in acquired and perioperative bleeding. In: Kietaibl SA, Ed Uni-Med Verlag AG Bremen London Boston. 2018; pp. 77- 90.
[13]
Levy JH, Welsby I, Goodnough LT. Fibrinogen as a therapeutic target for bleeding: A review of critical levels and replacement therapy. Transfusion 2014; 54(5): 1389-405.
[http://dx.doi.org/10.1111/trf.12431] [PMID: 24117955]
[14]
Hiippala ST, Myllylä GJ, Vahtera EM. Hemostatic factors and replacement of major blood loss with plasma-poor red cell concentrates. Anesth Analg 1995; 81(2): 360-5.
[PMID: 7542432]
[15]
Costa-Filho R, Hochleitner G, Wendt M, Teruya A, Spahn DR. Over 50 years of fibrinogen concentrate. Clin Appl Thromb Hemost 2016; 22(2): 109-14.
[http://dx.doi.org/10.1177/1076029615601494] [PMID: 26294722]
[16]
Schenk B, Lindner AK, Treichl B, et al. Fibrinogen supplementation ex vivo increasesclot firmness comparable to platelet transfusion in thrombocytopenia. Br J Anaesth 2016; 117(5): 576-82.
[http://dx.doi.org/10.1093/bja/aew315] [PMID: 27799172]
[17]
Adelmann D, Klaus DA, Illievich UM, et al. Fibrinogen but not factor XIII deficiency is associated with bleeding after craniotomy. Br J Anaesth 2014; 113(4): 628-33.
[http://dx.doi.org/10.1093/bja/aeu133] [PMID: 24871873]
[18]
Tatsuno J, Komatsu T, Iida S. Pharmacokinetic studies of argipidine (MD-805) - protein binding and blood cell binding. Jap Pharmacol Therap 1986; 15(Suppl.): 243-9.
[19]
Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 2000; 20(3): 318-29.
[http://dx.doi.org/10.1592/phco.20.4.318.34881] [PMID: 10730687]
[20]
Link A, Girndt M, Selejan S, Mathes A, Böhm M, Rensing H. Argatroban for anticoagulation in continuous renal replacement therapy. Crit Care Med 2009; 37(1): 105-10.
[http://dx.doi.org/10.1097/CCM.0b013e3181932394] [PMID: 19050602]
[21]
Staples MH, Dunton RF, Karlson KJ, Leonardi HK, Berger RL. Heparin resistance after preoperative heparin therapy or intraaortic balloon pumping. Ann Thorac Surg 1994; 57(5): 1211-6.
[http://dx.doi.org/10.1016/0003-4975(94)91359-5] [PMID: 8179387]
[22]
Anderson JAM, Saenko EL. Heparin resistance. Br J Anaesth 2002; 88(4): 467-9.
[http://dx.doi.org/10.1093/bja/88.4.467] [PMID: 12066718]
[23]
Fries D. Thrombosis prophylaxis in critically ill patients. Wien Med Wochenschr 2011; 161(3-4): 68-72.
[http://dx.doi.org/10.1007/s10354-011-0878-6] [PMID: 21404142]
[24]
Chan T, Hwang NC, Lim CH. A statistical analysis of factors predisposing patients to heparin resistance. Perfusion 2006; 21(2): 99-103.
[http://dx.doi.org/10.1191/0267659106pf855oa] [PMID: 16615687]
[25]
Oudemans-van Straaten HM, Kellum JA, Bellomo R. Clinical review: Anticoagulation for continuous renal replacement therapy--heparin or citrate? Crit Care 2011; 15(1): 202.
[http://dx.doi.org/10.1186/cc9358] [PMID: 21345279]
[26]
Alban S. Pharmakologie der Heparine und der direkten Antikoagulanzien. Hamostaseologie 2008; 28(5): 400-20.
[http://dx.doi.org/10.1055/s-0037-1617187] [PMID: 19132170]
[27]
Kaku B, Katsuda S, Taguchi T, Nitta Y, Hiraiwa Y. A case of acute myocardial infarction with repetitive stent thrombosis during emergent percutaneous coronary intervention. Transient decrease in antithrombin III activity and heparin resistance. Int Heart J 2009; 50(1): 111-9.
[http://dx.doi.org/10.1536/ihj.50.111] [PMID: 19246851]
[28]
Mejak B, Giacomuzzi C, Shen I, Boshkov L, Ungerleider R. Cardiopulmonary bypass using argatroban as an anticoagulant for a 6.0-kg pediatric patient. J Extra Corpor Technol 2005; 37(3): 303-5.
[PMID: 16350385]
[29]
Kozek-Langenecker S, Fries D, Gütl M, et al. Klinischer Erfahrungsaustausch für die Praxis: Argatroban bei Heparinunverträglichkeit. Wiener Klinisches Magazin 2014; 2: 42-5.
[30]
Baxalta Innovations Gmb H. Veyvondi Summary of Product Characteristics https://www.ema.europa.eu/documents/product-information/veyvondi-epar-product-information_en.pdf
[31]
Keesler DA, Flood VH. Current issues in diagnosis and treatment of von Willebrand disease. Res Pract Thromb Haemost 2017; 2(1): 34-41.
[http://dx.doi.org/10.1002/rth2.12064] [PMID: 30046704]
[32]
Chapin J. Von Willebrand disease in the elderly: Clinical perspectives. Clin Interv Aging 2018; 13: 1531-41.
[http://dx.doi.org/10.2147/CIA.S136931] [PMID: 30214173]
[34]
Knoebl P, Marco P, Baudo F, et al. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). J Thromb Haemost 2012; 10(4): 622-31.
[http://dx.doi.org/10.1111/j.1538-7836.2012.04654.x] [PMID: 22321904]
[35]
Franchini M, Mannucci PM. Acquired haemophilia A: A 2013 update. Thromb Haemost 2013; 110(6): 1114-20.
[http://dx.doi.org/10.1160/TH13-05-0363] [PMID: 24008306]
[36]
Kruse-Jarres R, Kempton CL, Baudo F, et al. Acquired hemophilia A: Updated review of evidence and treatment guidance. Am J Hematol 2017; 92(7): 695-705.
[http://dx.doi.org/10.1002/ajh.24777] [PMID: 28470674]
[37]
Franchini M, Vaglio S, Marano G, et al. Acquired hemophilia A: A review of recent data and new therapeutic options. Hematology 2017; 22(9): 514-20.
[http://dx.doi.org/10.1080/10245332.2017.1319115] [PMID: 28441921]
[38]
Batty P, Moore GW, Platton S, et al. Diagnostic accuracy study of a factor VIII ELISA for detection of factor VIII antibodies in congenital and acquired haemophilia A. Thromb Haemost 2015; 114(4): 804-11.
[http://dx.doi.org/10.1160/TH14-12-1062] [PMID: 26063073]
[39]
Kruse-Jarres R, St-Louis J, Greist A, et al. Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A. Haemophilia 2015; 21(2): 162-70.
[http://dx.doi.org/10.1111/hae.12627] [PMID: 25623166]
[40]
Standing Committee on Education and Professional Development of the Section and Board of Anaesthesiology European Trainng Requirement ETR in Anaesthesiology https://www.uems.eu/__data/assets/pdf_file/0003/64398/UEMS-2018.17-European-Training-Requirements-in-Anaesthesiology.pdf
[41]
Kozek-Langenecker SA. Perioperative management issues of direct oral anticoagulants. Semin Hematol 2014; 51(2): 112-20.
[http://dx.doi.org/10.1053/j.seminhematol.2014.02.001] [PMID: 24861795]
[42]
Eikelboom JW, Kozek-Langenecker S, Exadaktylos A, et al. Emergency care of patients receiving non-vitamin K antagonist oral anticoagulants. Br J Anaesth 2018; 120(4): 645-56.
[http://dx.doi.org/10.1016/j.bja.2017.11.082] [PMID: 29576106]
[43]
Schiele F, van Ryn J, Canada K, et al. A specific antidote for dabigatran: Functional and structural characterization. Blood 2013; 121(18): 3554-62.
[http://dx.doi.org/10.1182/blood-2012-11-468207] [PMID: 23476049]
[44]
Glund S, Stangier J, Schmohl M, et al. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: A randomised, placebo-controlled, double-blind phase 1 trial. Lancet 2015; 386(9994): 680-90.
[http://dx.doi.org/10.1016/S0140-6736(15)60732-2] [PMID: 26088268]
[45]
Glund S, Stangier J, van Ryn J, et al. Restarting dabigatran etexilate 24 h after reversal with idarucizumab and redosing idarucizumab in healthy volunteers. J Am Coll Cardiol 2016; 67(13): 1654-6.
[http://dx.doi.org/10.1016/j.jacc.2016.01.043] [PMID: 27150693]
[46]
Schmohl M, Glund S, Harada A, et al. Idarucizumab does not have procoagulant effects: Assessment of thrombosis biomarkers in healthy volunteers. Thromb Haemost 2017; 117(2): 269-76.
[http://dx.doi.org/10.1160/TH16-05-0385] [PMID: 27904905]
[47]
Pollack CV Jr, Reilly PA, van Ryn J, et al. Idarucizumab for dabigatran reversalefull cohort analysis. N Engl J Med 2017; 377(5): 431-41.
[http://dx.doi.org/10.1056/NEJMoa1707278] [PMID: 28693366]
[48]
Glund S, Moschetti V, Norris S, et al. A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. Thromb Haemost 2015; 113(5): 943-51.
[http://dx.doi.org/10.1160/TH14-12-1080] [PMID: 25789661]
[49]
Boehringer Ingelheim International GmbH. Praxbind Summary of Product Characteristics https://www.ema.europa.eu/documents/product-information/praxbind-epar-product-information_en.pdf.
[50]
Eikelboom JW, Quinlan DJ, van Ryn J, Weitz JI. Idarucizumab: the antidote for reversal of dabigatran. Circulation 2015; 132(25): 2412-22.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.115.019628] [PMID: 26700008]
[51]
Connolly SJ, Milling TJ Jr, Eikelboom JW, et al. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med 2016; 375(12): 1131-41.
[http://dx.doi.org/10.1056/NEJMoa1607887] [PMID: 27573206]
[52]
Costin J, Ansell J, Laulicht B, Bakhru S, Steiner S. Reversal agents in development for the new oral anticoagulants. Postgrad Med 2014; 126(7): 19-24.
[http://dx.doi.org/10.3810/pgm.2014.11.2829] [PMID: 25387210]
[53]
Ponschab M, Voelckel W, Pavelka M, Schlimp CJ, Schöchl H. Effect of coagulation factor concentrate administration on ROTEM® parameters in major trauma. Scand J Trauma Resusc Emerg Med 2015; 23: 84.
[http://dx.doi.org/10.1186/s13049-015-0165-4] [PMID: 26514413]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 25
ISSUE: 19
Year: 2019
Page: [2158 - 2164]
Pages: 7
DOI: 10.2174/1381612825666190708183127
Price: $65

Article Metrics

PDF: 32
HTML: 3
EPUB: 1
PRC: 1

Special-new-year-discount